31 July 2023
Delivering on the Promise of Cell and Gene Therapy Distributed and Point-of-Care Manufacturing
At Advanced Therapies Week 2023, Carol Houts, Chief Strategy Officer at Germfree, sat down with a few invited guests at the Germfree booth to discuss the challenges and opportunities associated with delivering cell therapies in a distributed and point-of-care manufacturing models. Watch the full series, below.
Latest Content
Don’t Miss Out on Our Latest Webinar
Up Next: Unlock the Future of Advanced Therapeutics: Considerations for Developing Global Manufacturing Capacity
Join the discussion of what to consider when developing a global manufacturing capacity
27 Jul 2023
Thursday, July 27, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]
Our eBooks & Infographics
Pioneering the future: a compendium of the top Phase I biotech companies at the forefront of innovation within advanced therapies.
This Case study demonstrates the importance of the cell processing and cell culture workflow steps required to improve and develop cell therapies whilst meeting regulatory compliance, increasing speed and reducing costs.
This Case Study demonstrates how the pressures of CDMOs to support their clients can be intense. GeminiBio discusses the importance of the ability of CDMOs to manage their processes whilst accommodating to their client’s needs as well as other factors that may affect the their ability to demonstrate flexibility.
For this article, PROGEN’s Dana Holzinger (Head of Product Management), Katja Betts (CEO) and Caroline Odenwald (Head of Marketing) discuss the need to anticipate change when developing AAV gene therapy to reduce uncertainty whilst still supporting innovation and resilience as the path to success can be complex with many challenges.
As manufacturing pipelines scale in line with increased demand for advanced therapies, there is further demand for digital solutions to support complex manufacturing process development.
Exploring digital solutions for cell and gene therapy manufacturing: a Pharma 4.0 perspective.
This Case Study demonstrates how the Association for the Advancement of Blood & Biotherapeutics (AABB) evaluated the apparent challenges in identifying and retaining employees due to a shortage in the worldwide biotherapies workforce.
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment.
